Literature DB >> 25608711

p21 ablation in liver enhances DNA damage, cholestasis, and carcinogenesis.

Haksier Ehedego1, Mark V Boekschoten2, Wei Hu1, Carina Doler3, Johannes Haybaeck3, Nikolaus Gaβler4, Michael Müller2, Christian Liedtke1, Christian Trautwein5.   

Abstract

Genetic mouse studies suggest that the NF-κB pathway regulator NEMO (also known as IKKγ) controls chronic inflammation and carcinogenesis in the liver. However, the molecular mechanisms explaining the function of NEMO are not well defined. Here, we report that overexpression of the cell-cycle regulator p21 is a critical feature of liver inflammation and carcinogenesis caused by the loss of NEMO. NEMO(Δhepa) mice develop chronic hepatitis characterized by increased hepatocyte apoptosis and proliferation that causes the development of fibrosis and hepatocellular carcinoma (HCC), similar to the situation in human liver disease. Having identified p21 overexpression in this model, we evaluated its role in disease progression and LPS-mediated liver injury in double mutant NEMO(Δhepa)/p21(-/-) mice. Eight-week-old NEMO(Δhepa)/p21(-/-) animals displayed accelerated liver damage that was not associated with alterations in cell-cycle progression or the inflammatory response. However, livers from NEMO(Δhepa)/p21(-/-) mice displayed more severe DNA damage that was further characterized by LPS administration correlating with higher lethality of the animals. This phenotype was attenuated by genetic ablation of the TNF receptor TNF-R1 in NEMO(Δhepa)/p21(-/-) mice, demonstrating that DNA damage is induced via TNF. One-year-old NEMO(Δhepa)/p21(-/-) mice displayed greater numbers of HCC and severe cholestasis compared with NEMO(Δhepa) animals. Therefore, p21 overexpression in NEMO(Δhepa) animals protects against DNA damage, acceleration of hepatocarcinogenesis, and cholestasis. Taken together, our findings illustrate how loss of NEMO promotes chronic liver inflammation and carcinogenesis, and they identify a novel protective role for p21 against the generation of DNA damage. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25608711     DOI: 10.1158/0008-5472.CAN-14-1356

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

Review 1.  Hepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes.

Authors:  Yuan-Chi Teng; Zhao-Qing Shen; Cheng-Heng Kao; Ting-Fen Tsai
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

2.  Long noncoding RNA uc.338 promotes cell proliferation through association with BMI1 in hepatocellular carcinoma.

Authors:  Changwen Bo; Na Li; Xiuli Li; Xianwei Liang; Yonghui An
Journal:  Hum Cell       Date:  2016-05-06       Impact factor: 4.174

3.  Loss of Cyclin E1 attenuates hepatitis and hepatocarcinogenesis in a mouse model of chronic liver injury.

Authors:  Haksier Ehedego; Antje Mohs; Bettina Jansen; Kanishka Hiththetiya; Piotr Sicinski; Christian Liedtke; Christian Trautwein
Journal:  Oncogene       Date:  2018-03-19       Impact factor: 9.867

4.  Epidermal ROCK2 induces AKT1/GSK3β/β-catenin, NFκB and dermal tenascin C; but enhanced differentiation and p53/p21 inhibit papilloma.

Authors:  Siti F Masre; Nicola Rath; Michael F Olson; David A Greenhalgh
Journal:  Carcinogenesis       Date:  2020-10-15       Impact factor: 4.944

5.  p21 in chronic and acute liver injury.

Authors:  Haksier Ehedego; Christian Trautwein
Journal:  Oncoscience       Date:  2016-03-04

6.  Kallikrein-related peptidase 6 induces chemotherapeutic resistance by attenuating auranofin-induced cell death through activation of autophagy in gastric cancer.

Authors:  Tae Woo Kim; Seon-Jin Lee; Jong-Tae Kim; Sun Jung Kim; Jeong-Ki Min; Kwang-Hee Bae; Haiyoung Jung; Bo-Yeon Kim; Jong-Seok Lim; Young Yang; Do-Young Yoon; Yong-Kyung Choe; Hee Gu Lee
Journal:  Oncotarget       Date:  2016-12-20

7.  c-Myc regulates the CDK1/cyclin B1 dependent‑G2/M cell cycle progression by histone H4 acetylation in Raji cells.

Authors:  Yan Yang; Kai Xue; Zhi Li; Wei Zheng; Weijie Dong; Jiazhe Song; Shijie Sun; Tonghui Ma; Wenzhe Li
Journal:  Int J Mol Med       Date:  2018-02-28       Impact factor: 5.314

8.  Disruption of the FasL/Fas axis protects against inflammation-derived tumorigenesis in chronic liver disease.

Authors:  Francisco Javier Cubero; Marius Maximilian Woitok; Miguel E Zoubek; Alain de Bruin; Maximilian Hatting; Christian Trautwein
Journal:  Cell Death Dis       Date:  2019-02-08       Impact factor: 8.469

Review 9.  p21 in Cancer Research.

Authors:  Bahar Shamloo; Sinem Usluer
Journal:  Cancers (Basel)       Date:  2019-08-14       Impact factor: 6.639

10.  NCOA5 deficiency promotes a unique liver protumorigenic microenvironment through p21WAF1/CIP1 overexpression, which is reversed by metformin.

Authors:  Mark Williams; Xinhui Liu; Yueqi Zhang; Jake Reske; Devika Bahal; Trevor G Gohl; Daniel Hollern; Elliot Ensink; Matti Kiupel; Rongcheng Luo; Rupali Das; Hua Xiao
Journal:  Oncogene       Date:  2020-03-20       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.